Immunovant, Inc. IMVT Cash Flow Statement
| FY'26 | FY'25 | FY'24 | FY'23 | ||
|---|---|---|---|---|---|
| -$505.61M-22.2% | -$413.84M-59.6% | -$259.34M-22.9% | -$210.96M-34.6% | ||
| $409K+8.5% | $377K+63.2% | $231K+19.7% | $193K+53.2% | ||
| $55.72M+12.6% | $49.49M+20.4% | $41.12M+27.3% | $32.3M-5.7% | ||
| -$407.31M-8.4% | -$375.87M-75.5% | -$214.23M-13.8% | -$188.19M-77.4% | ||
| $8K-98.9% | $759K+111% | $360K+82.7% | $197K-22.4% | ||
| -$8K+98.9% | -$759K-111% | -$360K-82.7% | -$197K+22.4% | ||
| $595.76M+31.1% | $454.49M-3.8% | $472.43M+566% | $70.89M— | ||
| —— | $78.61M— | —— | —— | ||
| -$407.32M-8.1% | -$376.63M-75.5% | -$214.59M-13.9% | -$188.39M-77.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Immunovant, Inc. generate?
- Immunovant, Inc. (IMVT) generated -$407.3M in operating cash flow over the trailing twelve months.
- What is Immunovant, Inc.'s free cash flow?
- After $8.0K of capital expenditures, Immunovant, Inc.'s free cash flow was -$407.3M over the trailing twelve months, down 8.2% year over year.
- Where does Immunovant, Inc.'s cash flow data come from?
- Every line is extracted from Immunovant, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.